Identifying predictors of durable treatment response among patients with claudication: A secondary analysis of the CLEVER trial
Among randomized patients in the CLEVER trial, treatment with either SET or stenting was predictive of clinically meaningful change in the PAQ summary score from baseline to 6 and 18 months. These interventions, with a prioritization of SET, should be more widely available to patients with PAD. This study adds to the findings of the CLEVER trial by denoting that SET and stenting are beneficial in patients with PAD, independent of comorbidities.
Authors
- Michael D. Murphy (ORCID: https://orcid.org/0000-0001-5609-7364)
- Timothy P. Murphy (ORCID: https://orcid.org/0000-0002-8028-6410)
- Brett Carroll (ORCID: https://orcid.org/0000-0002-6704-5663)
- Eric A. Secemsky (ORCID: https://orcid.org/0000-0003-3861-3163)
- Firas Hentati (ORCID: https://orcid.org/0000-0003-3471-3933)
Institutions
- Boston College (US)
- Beth Israel Deaconess Medical Center (US)
- Harvard University (US)
- Deaconess Hospital (US)
Publication Details
- Journal
- Vascular Medicine
- Published
- 2025-05-26
- DOI
- https://doi.org/10.1177/1358863x251333932
- Primary Topic
- Peripheral Artery Disease Management
- Type
- article
- Field-Weighted Citation Impact
- 0.00